SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                    FORM 8-K


                                 Current Report
                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934


      Date of Report (Date of earliest event reported): September 11, 2001


                                 CRYOLIFE, INC.
             (Exact name of registrant as specified in its charter)


                                     Florida
                 (State or other jurisdiction of incorporation)


      1-13165                                     59-2417093
  (Commission File Number)              (IRS Employer Identification No.)


              1655 Roberts Boulevard, N.W., Kennesaw, Georgia 30144
          (Address of principal executive offices, including zip code)


                                 (770) 419-3355
              (Registrant's telephone number, including area code)


                        --------------------------------
          (Former name or former address, if changed since last report)






Item 9.  Regulation FD Disclosure.

     On  September  11,  2001,  The U.S.  Food and Drug  Administration's  (FDA)
Circulatory  System Devices Panel  unanimously  recommended to approve  CryoLife
Inc.'s BioGlue Surgical Adhesive as an adjunct to the use of sutures and staples
in vascular and cardiac repair to achieve hemostasis. The Panel's recommendation
will be reviewed by the FDA, which is ultimately responsible for market approval
decisions.

     In December  1999,  BioGlue  was made  available  in the U.S.  under an FDA
approved  Humanitarian  Device  Exemption for use as an adjunct in the repair of
acute  thoracic  aortic  dissections,  a  life-threatening  condition.  For this
indication, BioGlue has received Institutional Review Board (IRB) approval to be
shipped to over 600 hospitals in the United States. Internationally,  BioGlue is
currently  approved in 36 foreign  countries  for use in vascular and  pulmonary
repair and to provide more effective hemostasis control.

     Pursuant  to the  rules of the  Securities  and  Exchange  Commission,  the
information  contained  in this  report  shall  not be  deemed  "filed"  for the
purposes of Section 18 of the Securities  Exchange Act of 1934, as amended,  and
will not be  incorporated by reference into any filing of the Company under such
Act or the Securities Act of 1933, as amended.

     Statements   made  herein  that  look  forward  in  time  or  that  express
management's  beliefs,  expectations or hopes regarding  future  occurrences are
forward-looking   statements  within  the  meaning  of  the  Private  Securities
Litigation  Reform Act of 1995. These future events may not occur when expected,
if at all, and are subject to various  risks and  uncertainties.  Such risks and
uncertainties  include the possibility  that the FDA may not ultimately  approve
BioGlue  Surgical  Adhesive  as an adjunct to the use of sutures  and staples in
vascular  and  cardiac   repair  to  achieve   hemostasis  or  for  the  general
distribution of BioGlue Surgical Adhesive and other risk factors detailed in the
Company's  Securities and Exchange Commission  filings,  including the Company's
Form 10-K for the year ended December 31, 2000.







                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                              CRYOLIFE, INC.



Date:  September 13, 2001            By:  /s/ Steven G. Anderson
                                         ----------------------------------
                                         Name:    Steven G. Anderson
                                         Title:   President, Chief Executive
                                                  Officer and Chairman



1395470v1